<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00738972</url>
  </required_header>
  <id_info>
    <org_study_id>MK-0653A-168</org_study_id>
    <secondary_id>2008_020</secondary_id>
    <nct_id>NCT00738972</nct_id>
    <nct_alias>NCT00621127</nct_alias>
  </id_info>
  <brief_title>Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients (MK0653A-168)</brief_title>
  <official_title>Left Ventricular Hypertrophy Reduction With Statins in Hypertensives Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundaci贸n Lindavista del Coraz贸n AC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundaci贸n Lindavista del Coraz贸n AC</source>
  <brief_summary>
    <textblock>
      Evaluate pleiotropic effects of simvastatin in hypertensive patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated early due to sample size, not possible to perform further statistical
    analysis.
  </why_stopped>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients</measure>
    <time_frame>6 Month(s)</time_frame>
    <description>Left ventricular hypertrophy reduction was to be measured by echocardiography.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Valsartan 80 mg + Paravastin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 80 mg + Simvastatin 40 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>valsartan</intervention_name>
    <description>80 mg valsartan. Duration: 12 months. Tablets</description>
    <arm_group_label>Valsartan 80 mg + Paravastin 40 mg</arm_group_label>
    <arm_group_label>Valsartan 80 mg + Simvastatin 40 mg</arm_group_label>
    <arm_group_label>Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg</arm_group_label>
    <arm_group_label>Valsartan 80 mg</arm_group_label>
    <other_name>Diovan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pravastatin</intervention_name>
    <description>40 mg pravastatin. Duration: 12 months. Tablets</description>
    <arm_group_label>Valsartan 80 mg + Paravastin 40 mg</arm_group_label>
    <other_name>Pravacol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>simvastatin</intervention_name>
    <description>40 mg simvastatin. Duration: 12 months. Tablets</description>
    <arm_group_label>Valsartan 80 mg + Simvastatin 40 mg</arm_group_label>
    <other_name>Zocor</other_name>
    <other_name>MK0733</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ezetimibe (+) simvastatin</intervention_name>
    <description>ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets</description>
    <arm_group_label>Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg</arm_group_label>
    <other_name>vytorin</other_name>
    <other_name>MK0653A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females Or Males Over 18 Years Old

          -  Patients With Systemic Arterial Hypertension Grade I And II According With The
             European Society Of Cardiology

          -  Left Ventricular hypertrophy Demonstrated By Echocardiography

          -  Mild To Moderated hypercholesterolemia

          -  Willing To Participate And Sign The Informed Consent Form (ICF)

        Exclusion Criteria:

          -  Type 1 Or 2 Diabetes Mellitus

          -  Familiar hypercholesterolemia

          -  Low Density Lipoprotein-Cholesterol (LDL-C) &gt; 190 mg/dl

          -  History Of Myocardial Infarction Or Stable Chronic Angina

          -  Triglycerides &gt;250 mg/dl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Mexico</country>
  </removed_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 19, 2008</study_first_submitted>
  <study_first_submitted_qc>August 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2008</study_first_posted>
  <results_first_submitted>July 20, 2013</results_first_submitted>
  <results_first_submitted_qc>July 20, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 13, 2013</results_first_posted>
  <disposition_first_submitted>August 16, 2011</disposition_first_submitted>
  <disposition_first_submitted_qc>August 16, 2011</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 23, 2011</disposition_first_posted>
  <last_update_submitted>August 17, 2013</last_update_submitted>
  <last_update_submitted_qc>August 17, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Hypertrophy, Left Ventricular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Valsartan 80 mg + Paravastin 40 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)</description>
        </group>
        <group group_id="P2">
          <title>Valsartan 80 mg + Simvastatin 40 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)</description>
        </group>
        <group group_id="P3">
          <title>Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)</description>
        </group>
        <group group_id="P4">
          <title>Valsartan 80 mg</title>
          <description>Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Valsartan 80 mg + Paravastin 40 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)</description>
        </group>
        <group group_id="B2">
          <title>Valsartan 80 mg + Simvastatin 40 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)</description>
        </group>
        <group group_id="B3">
          <title>Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)</description>
        </group>
        <group group_id="B4">
          <title>Valsartan 80 mg</title>
          <description>Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&gt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients</title>
        <description>Left ventricular hypertrophy reduction was to be measured by echocardiography.</description>
        <time_frame>6 Month(s)</time_frame>
        <population>This study was terminated early and due to sample size it was not possible to perform further statistical analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Valsartan 80 mg + Paravastin 40 mg</title>
            <description>Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)</description>
          </group>
          <group group_id="O2">
            <title>Valsartan 80 mg + Simvastatin 40 mg</title>
            <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)</description>
          </group>
          <group group_id="O3">
            <title>Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg</title>
            <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)</description>
          </group>
          <group group_id="O4">
            <title>Valsartan 80 mg</title>
            <description>Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)</description>
          </group>
        </group_list>
        <measure>
          <title>Left Ventricular Hypertrophy Reduction With Statins in Hypertensive Patients</title>
          <description>Left ventricular hypertrophy reduction was to be measured by echocardiography.</description>
          <population>This study was terminated early and due to sample size it was not possible to perform further statistical analyses.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Valsartan 80 mg + Paravastin 40 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus paravastin 40 mg by mouth daily for one year. (Group A)</description>
        </group>
        <group group_id="E2">
          <title>Valsartan 80 mg + Simvastatin 40 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg by mouth daily for one year. (Group B)</description>
        </group>
        <group group_id="E3">
          <title>Valsartan 80 mg + Simvastatin 40 mg / Ezetimibe 10 mg</title>
          <description>Participants who were administered Valsartan 80 mg plus simvastatin 40 mg / ezetimibe 10 mg by mouth daily for one year. (Group C)</description>
        </group>
        <group group_id="E4">
          <title>Valsartan 80 mg</title>
          <description>Participants who were administered Valsartan 80 mg by mouth daily for one year. (Group D)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early and due to sample size it was not possible to perform further statistical analyses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Vice President, Late Stage Development Group Leader</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

